ZIVO
ZIVO Bioscience, Inc.9.00
+0.00+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
35.00MP/E (TTM)
-Basic EPS (TTM)
-2.18Dividend Yield
0%Recent Filings
8-K
8-K
CFO resigns; interim named
Zivo Bioscience's CFO Keith Marchiando resigned effective immediately on December 19, 2025, with employment ending December 31, 2025; he secures $27,040 monthly pay through 2026 and retains options for 150,000 shares at $7.96 exercisable to June 2027. Biotech veteran William Sullivan steps in as interim CFO at $285/hour under a 60-day contract, auto-renewing monthly. Leadership shifts swiftly. Sullivan's 25 years stabilize finances amid transition.
10-Q
Q3 FY2025 results
Zivo Bioscience posted Q3 revenue of $65.6k, up 108% y/y from $31.5k, with gross margin doubling to $21.3k; yet operating loss narrowed to $1.0M from $2.3M as G&A plunged 57% on lower equity comp and R&D eased 38%. YTD revenue climbed 77% to $119k, but net loss hit $6.9M versus $11.8M prior, driven by $2.7M exchange agreement expenses. Cash dwindled to $57k after $2.2M operating burn, offset by $688k financing including $250k convertible note at 10%. Leases signed in Jan 2025 for labs in Florida (36 months) and Michigan (63 months). Equity dilution persists. Cash won't last.
8-K
Algae tech breakthroughs validated
Zivo Bioscience issued a CEO letter on September 10, 2025, touting breakthrough validation of its algae technology, showing nearly double superoxide dismutase activity versus competitors, alongside rich antioxidants like beta-carotene and lutein. This positions the company for growth in human nutrition via active nutraceutical talks and animal health through proven immune boosts in poultry trials that delay avian influenza spread. Yet liquidity challenges persist amid capital-raising efforts. Ongoing studies could reshape markets.
8-K
Board Resignation Hits Zivo
Zivo Bioscience's board saw a sudden shift on August 12, 2025, when Nola Masterson resigned immediately as director, chair of the Nominating and Governance Committee, and member of Audit and Compensation—yet without any disputes over operations or policies. No replacement has been named, leaving the seat open amid the biotech's ongoing challenges. Smooth transition, for now.
IPO
Employees
Sector
Industry
ADPT
Adaptive Biotechnologies Corpor
15.93+0.24
BDPT
Bioadaptives, Inc.
0.03+0.00
BIOE
Bio Essence Corp.
0.05+0.00
BIVI
BioVie Inc.
1.43+0.00
IBO
Impact BioMedical, Inc.
0.44-0.02
LEXX
Lexaria Bioscience Corp.
0.84-0.05
NAGE
Niagen Bioscience, Inc.
6.34-0.03
PETV
PetVivo Holdings Inc.
1.16-0.03
VIVS
VivoSim Labs, Inc.
1.99+0.01
ZEOX
Zeo ScientifiX Inc.
1.99+0.18